Reference

Treatment of allergic rhinitis and asthma with atomoxetine

Treatment of allergic rhinitis and asthma with atomoxetine. Dunaway, Leslie Joe (USA ). PCT Int. Appl. WO 2005011583 A2 10 Feb 2005,9 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English).In this article, certain chemicals are used. Some of their cas registry numbers are 83015-26-3 and 82248-59-7 (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K. APPLICATION: WO 2004-US24125 27 Jul 2004. PRIORITY: US 2003-PV490644 28 Jul 2003. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) This invention provides a method of treating allergic rhinitis in a mammal comprising administering a therapeutically effective amt. of atomoxetine to a mammal in need of such treatment, and also provides a method of treating asthma in a mammal comprising administering a therapeutically effective amt. of atomoxetine to a mammal in need of such treatment. .

Atomoxetine treatment of attention-deficit/hyperactivity disorder

Atomoxetine treatment of attention-deficit/hyperactivity disorder. Eiland, Lea S.; Guest, Abby L. (Harrison School of Pharmacy, Auburn Univ., Huntsville, AL, USA). Annals of Pharmacotherapy, 38(1), 86-90 (English) 2004 Harvey Whitney Books Co. CODEN: APHRER.Some commonly used reagents like 82248-59-7 and 51-41-2 are used in this experiment. ISSN: 1060-0280. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Objective: To review the literature of the first nonstimulant approved for treatment of attention-deficit/hyperactivity disorder (ADHD). Data Sources: Primary literature and review articles were obtained through PubMed/MEDLINE (1966-Feb. 2003). Study Selection and Data Extn.: Literature evaluating atomoxetine in ADHD was selected. Animal data were excluded. Data Synthesis: Stimulants are currently first-line therapy for ADHD. However, their use raises several concerns including the potential for abuse and adverse effects. Atomoxetine introduces a new therapeutic drug class, selective norepinephrine-reuptake inhibitors, for ADHD management. This addnl. treatment option offers potential advantages over current therapies. Conclusions: Clin. trials demonstrate that atomoxetine is a safe and effective alternative for ADHD treatment in children and adults; however, its disadvantages may hinder it from becoming a first-line agent. .